What Is Ipamorelin?

Ipamorelin (NNC 26-0161) is a synthetic pentapeptide — five amino acids — that acts as a selective agonist at the growth hormone secretagogue receptor (GHS-R1a). It binds a receptor in the pituitary gland and hypothalamus and triggers a pulse of growth hormone release.

Its defining feature is selectivity. Earlier growth hormone releasing peptides — GHRP-2, GHRP-6, hexarelin — also stimulated GH release but came with side effects: cortisol spikes, prolactin elevation, and in GHRP-6's case, a significant appetite stimulation effect through central ghrelin pathways. Ipamorelin was developed by Novo Nordisk specifically to retain the GH-releasing activity while avoiding those off-target effects. In animal studies, that selectivity largely held.

The downstream effects of elevated GH are what most users are actually after: increased IGF-1 production, which in turn drives muscle protein synthesis, fat metabolism, tissue repair, and some sleep architecture changes. Ipamorelin doesn't deliver those effects directly — it triggers the pituitary to release GH in pulses, which then signals the liver to produce IGF-1. It's one step removed from the actual growth factors most people care about.

What Does the Research Say?

Evidence level: Preliminary — Ipamorelin's mechanism and selectivity profile are well-established in animal studies and confirmed in small human pharmacodynamic work. Therapeutic outcome data in humans (body composition, recovery, anti-aging) does not exist in published trials. One clinical development program for postoperative ileus was discontinued without completing Phase III.

Animal Studies

The foundational characterization came from Novo Nordisk and was published by Raun et al. in the European Journal of Endocrinology (1998). The paper documented Ipamorelin's potent GH-releasing activity in rats and pigs alongside its selective receptor profile — minimal ACTH, cortisol, and prolactin effects compared to GHRP-2 and GHRP-6. This selectivity distinction was the core finding that justified Ipamorelin's development as a therapeutic candidate.

Bone density work by Svensson et al. (2000, Journal of Endocrinology) showed that 12 weeks of subcutaneous Ipamorelin in ovariectomized rats increased bone mineral content. GH secretagogues had been hypothesized to help offset age-related bone loss, and this study provided supporting data. Body composition data from rodent studies is consistent with what elevated GH/IGF-1 would predict: modest lean mass accrual and fat reduction at physiological doses.

GI motility studies are worth noting separately because they became the basis for the only human clinical program. Ipamorelin activates GHS-R1a receptors in the gut as well as the pituitary, and rodent studies showed it accelerated gastric emptying in gastroparesis models.

Human Studies

Human data on Ipamorelin is thin. The company that took it into clinical development pursued postoperative ileus (POI) as the indication — delayed return of bowel function after abdominal surgery, which extends hospital stays and increases complications. Phase II data were sufficiently promising to advance to Phase III. The Phase III program did not meet its primary endpoint in at least one pivotal trial, and development was discontinued. Full results from those trials were not published in peer-reviewed journals with named authorship in accessible form.

Outside of the POI program, small pharmacodynamic studies conducted in healthy volunteers (primarily by Novo Nordisk and affiliated centers in the late 1990s and early 2000s) confirmed that Ipamorelin produces GH pulses in humans consistent with what was seen in animals, and that the selectivity profile holds. These were not therapeutic outcome studies. Sample sizes were small.

There are no published human RCTs for the uses Ipamorelin is most commonly purchased for: body composition, injury recovery, sleep quality, or anti-aging. Those applications rest entirely on the GH physiology rationale and animal data.

Community and Anecdotal Reports

Ipamorelin is one of the most widely used peptides in biohacking communities, almost always stacked with CJC-1295 (without DAC). The combination aims to hit two complementary targets simultaneously — Ipamorelin stimulates GH release via the ghrelin receptor pathway, while CJC-1295 extends the GH pulse by acting on the GHRH receptor. Community reports describe improved sleep quality within a few weeks, faster recovery from training, and modest body composition changes over three to six months.

Self-reported outcomes are confounded by diet, training, variable product quality, and the significant placebo effect around anything affecting sleep and recovery. The reports are consistent directionally with what elevated GH/IGF-1 would produce, which makes them plausible — but not clinical evidence.

Common Uses

Growth Hormone Optimization

The core use case. Ipamorelin is used to amplify pulsatile GH secretion, most often as a strategy to counteract the natural decline in GH that begins in the third decade of life. The mechanism is real. Whether the GH increases produced at commonly used doses translate to clinically meaningful outcomes in healthy adults is not established.

Muscle Recovery and Body Composition

Elevated GH and IGF-1 accelerate muscle protein synthesis and fat mobilization. These are well-understood physiology in contexts of GH deficiency; whether the modest GH increases from Ipamorelin at wellness doses produce meaningful effects in healthy people with normal GH function is a separate question that has not been studied.

Sleep Quality

GH secretion naturally peaks during slow-wave sleep. Community users report deeper sleep and more vivid dreams, which they attribute to amplified GH pulses during that window. This is mechanistically plausible. No sleep studies have been conducted with Ipamorelin in humans.

Post-Surgery Recovery

Some physicians prescribe Ipamorelin in compounding contexts to support recovery after surgery, citing the tissue-repair downstream effects of elevated GH/IGF-1. The POI clinical program also suggested some GI motility benefit, though that program did not complete.

For a broader look at how peptides are being used in recovery contexts, see Peptides for Recovery: Do They Actually Work?.

Delivery Methods

Subcutaneous Injection

Subcutaneous injection is the standard and most validated route. The peptide is reconstituted from lyophilized powder in bacteriostatic water and injected into subcutaneous fat, typically the abdomen. Raun et al.'s original 1998 paper documented meaningful GH response via subcutaneous dosing in animals; the IV route produced a faster and sharper pulse but SC is the practical route for non-clinical use.

Timing matters for GH secretagogues. GH release is naturally suppressed by elevated blood glucose and insulin. Injecting Ipamorelin in a fasted state — either before sleep or in the morning before eating — is the community standard, based on the understanding that you can't amplify a GH pulse that insulin is already suppressing.

The peptide is not viable orally. Raun et al. showed some GH response with oral Ipamorelin in animal models, but bioavailability was substantially lower than subcutaneous and the approach has not been developed clinically. Intranasal routes have not been formally studied for Ipamorelin.

PEPVi does not provide dosing guidance. Dosing decisions should be made in consultation with a qualified healthcare provider.

Safety and Side Effects

The side effects most consistently reported from community use and animal studies are injection site reactions (redness, swelling, tenderness), water retention and mild facial or peripheral edema (a downstream GH effect), and occasional headache. Nausea occurs at higher doses but less frequently than with GHRP-6, consistent with Ipamorelin's reduced ghrelin pathway activity.

The theoretical concern worth taking seriously is what sustained IGF-1 elevation does over time. IGF-1 is a well-established risk factor for certain cancers. Exogenous recombinant GH at pharmacological doses carries documented risks including increased cancer incidence in long-term studies. Whether the more modest and physiologically patterned GH elevations from Ipamorelin at typical wellness doses carry similar risk is not known — it hasn't been studied. People with a personal or family history of cancer should discuss this specifically with a physician.

There is also the theoretical question of whether chronic GHS use suppresses endogenous GH secretion over time. The evidence here is mixed and the answer depends heavily on dose and duration. Short courses are generally considered lower risk on this front than indefinite use.

Long-term safety data for Ipamorelin in humans at wellness doses does not exist.

Ipamorelin is not FDA-approved for any indication. In October 2023, the FDA specifically proposed restricting Ipamorelin from compounding under 503A and 503B frameworks, citing insufficient safety data for human use. That action effectively removed the main legal access point for most US users through regulated compounding pharmacies.

Ipamorelin is one of the 12 peptides targeted in the current reclassification process. For what changes in July 2026, see What RFK's Peptide Reclassification Means for You.

Ipamorelin is not a scheduled controlled substance under DEA regulations. Outside the US, legal status varies by country and is generally tied to each jurisdiction's own compounding or pharmaceutical regulations.

Frequently Asked Questions

The two peptides act on different receptors in the GH axis. Ipamorelin acts on the ghrelin receptor (GHS-R1a), which triggers GH pulse release. CJC-1295 acts on the GHRH receptor, which extends the window of GH release. Used together, they hit both pathways simultaneously, producing a stronger and longer GH pulse than either alone. This combination is the dominant protocol in biohacking and wellness contexts.

Earlier peptides in the class (GHRP-2, GHRP-6, hexarelin) also stimulated GH release but triggered cortisol, prolactin, or appetite side effects that Ipamorelin largely avoids. That selectivity is Ipamorelin's defining feature and the reason it became the default GH secretagogue in wellness protocols. The trade-off is that it may be somewhat less potent than the first-generation GHRPs for pure GH release.

Elevated GH and IGF-1 affect body composition. Whether Ipamorelin at typical wellness doses raises GH and IGF-1 enough to produce measurable body composition changes — and whether those changes are meaningful beyond what diet and training achieve on their own — has not been studied in controlled trials. Community reports are positive but self-selected.

Short-term side effects are mild and well-tolerated by most users based on community reports. The more meaningful concerns are what chronic IGF-1 elevation does over years (cancer risk, acromegaly features at high doses) and whether endogenous GH axis function is affected with prolonged use. These questions are unresolved. Anyone with a cancer history should discuss this before use.

Learn More

Sources

  1. Raun K, Hansen BS, Johansen NL, et al. "Ipamorelin, the first selective growth hormone secretagogue." European Journal of Endocrinology, 1998. — Original characterization of Ipamorelin's selectivity profile in rats and pigs; established the compound's identity within the GHS class.

  2. Svensson J, Lall S, Dickson SL, et al. "The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats." Journal of Endocrinology, 2000. — 12-week rodent study showing increased bone mineral content with Ipamorelin administration.

  3. FDA. "Bulk Drug Substances Used in Compounding Under Section 503A." October 2023. — FDA proposed rule restricting Ipamorelin from 503A compounding; documents the regulatory action most relevant to US access.